RT Book, Section
A1 Damon, Lloyd E.
A1 Andreadis, Charalambos Babis
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
SR Print(0)
ID 1175800568
T1 Chronic Myeloid Leukemia
T2 Current Medical Diagnosis & Treatment 2021
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260469868
LK accessmedicine.mhmedical.com/content.aspx?aid=1175800568
RD 2022/06/28
AB Key  Clinical  Updates  in  Chronic  Myeloid  LeukemiaIn  patients  with  chronic  myeloid  leukemia  who  have  not  responded  to  treatment  with  multiple  tyrosine  kinase  inhibitors,  the  novel  allosteric  inhibitor  asciminib  can  be  tried.  It  has  shown  a  54%  complete  hematologic  response  rate  and  a  48%  sustained  major  molecular  response  in  heavily  pretreated  patients.